BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

465 related articles for article (PubMed ID: 12408709)

  • 21. Structural basis for therapeutic intervention of uPA/uPAR system.
    Ngo JC; Jiang L; Lin Z; Yuan C; Chen Z; Zhang X; Yu H; Wang J; Lin L; Huang M
    Curr Drug Targets; 2011 Nov; 12(12):1729-43. PubMed ID: 21707478
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Kinetics of reciprocal pro-urokinase/plasminogen activation--stimulation by a template formed by the urokinase receptor bound to poly(D-lysine).
    Petersen LC
    Eur J Biochem; 1997 Apr; 245(2):316-23. PubMed ID: 9151959
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cell-surface acceleration of urokinase-catalyzed receptor cleavage.
    Høyer-Hansen G; Ploug M; Behrendt N; Rønne E; Danø K
    Eur J Biochem; 1997 Jan; 243(1-2):21-6. PubMed ID: 9030717
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Crystal structure of the human urokinase plasminogen activator receptor bound to an antagonist peptide.
    Llinas P; Le Du MH; Gårdsvoll H; Danø K; Ploug M; Gilquin B; Stura EA; Ménez A
    EMBO J; 2005 May; 24(9):1655-63. PubMed ID: 15861141
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Identification of specific sites involved in ligand binding by photoaffinity labeling of the receptor for the urokinase-type plasminogen activator. Residues located at equivalent positions in uPAR domains I and III participate in the assembly of a composite ligand-binding site.
    Ploug M
    Biochemistry; 1998 Nov; 37(47):16494-505. PubMed ID: 9843416
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Plasminogen activation by pro-urokinase in complex with its receptor--dependence on a tripeptide (Spectrozyme plasmin).
    Wang J; Mazar A; Quan N; Schneider A; Henkin J
    Eur J Biochem; 1997 Jul; 247(1):256-61. PubMed ID: 9249034
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Targeting multiple conformations leads to small molecule inhibitors of the uPAR·uPA protein-protein interaction that block cancer cell invasion.
    Khanna M; Wang F; Jo I; Knabe WE; Wilson SM; Li L; Bum-Erdene K; Li J; W Sledge G; Khanna R; Meroueh SO
    ACS Chem Biol; 2011 Nov; 6(11):1232-43. PubMed ID: 21875078
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Critical role of integrin alpha 5 beta 1 in urokinase (uPA)/urokinase receptor (uPAR, CD87) signaling.
    Tarui T; Andronicos N; Czekay RP; Mazar AP; Bdeir K; Parry GC; Kuo A; Loskutoff DJ; Cines DB; Takada Y
    J Biol Chem; 2003 Aug; 278(32):29863-72. PubMed ID: 12754207
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Urokinase plasminogen activator cleaves its cell surface receptor releasing the ligand-binding domain.
    Høyer-Hansen G; Rønne E; Solberg H; Behrendt N; Ploug M; Lund LR; Ellis V; Danø K
    J Biol Chem; 1992 Sep; 267(25):18224-9. PubMed ID: 1381366
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Structure-function relationships in the interaction between the urokinase-type plasminogen activator and its receptor.
    Ploug M
    Curr Pharm Des; 2003; 9(19):1499-528. PubMed ID: 12871065
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Designing tracers for PET imaging of the urokinase-type plasminogen activator receptor from a cyclic uPA-derived peptide: first in vitro evaluations.
    Wacker A; Bauder-Wüst U; Schäfer M; Schmidt J; Remde Y; Stadlbauer S; Eder M; Liolios C; Kopka K
    J Labelled Comp Radiopharm; 2019 Jun; 62(8):483-494. PubMed ID: 30970388
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Urokinase plasminogen activator induces human smooth muscle cell migration and proliferation via distinct receptor-dependent and proteolysis-dependent mechanisms.
    Stepanova V; Mukhina S; Köhler E; Resink TJ; Erne P; Tkachuk VA
    Mol Cell Biochem; 1999 May; 195(1-2):199-206. PubMed ID: 10395084
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Plasmin-dependent elimination of the growth-factor-like domain in urokinase causes its rapid cellular uptake and degradation.
    Poliakov A; Tkachuk V; Ovchinnikova T; Potapenko N; Bagryantsev S; Stepanova V
    Biochem J; 2001 May; 355(Pt 3):639-45. PubMed ID: 11311125
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A novel type of bifunctional inhibitor directed against proteolytic activity and receptor/ligand interaction. Cystatin with a urokinase receptor binding site.
    Muehlenweg B; Assfalg-Machleidt I; Parrado SG; Bürgle M; Creutzburg S; Schmitt M; Auerswald EA; Machleidt W; Magdolen V
    J Biol Chem; 2000 Oct; 275(43):33562-6. PubMed ID: 10913110
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A Cross Talk between Neuronal Urokinase-type Plasminogen Activator (uPA) and Astrocytic uPA Receptor (uPAR) Promotes Astrocytic Activation and Synaptic Recovery in the Ischemic Brain.
    Diaz A; Merino P; Manrique LG; Ospina JP; Cheng L; Wu F; Jeanneret V; Yepes M
    J Neurosci; 2017 Oct; 37(43):10310-10322. PubMed ID: 28931568
    [TBL] [Abstract][Full Text] [Related]  

  • 36. cDNA transfection of amino-terminal fragment of urokinase efficiently inhibits cancer cell invasion and metastasis.
    Zhu F; Jia S; Xing G; Gao L; Zhang L; He F
    DNA Cell Biol; 2001 May; 20(5):297-305. PubMed ID: 11410166
    [TBL] [Abstract][Full Text] [Related]  

  • 37. alpha-2 Macroglobulin receptor/Ldl receptor-related protein(Lrp)-dependent internalization of the urokinase receptor.
    Conese M; Nykjaer A; Petersen CM; Cremona O; Pardi R; Andreasen PA; Gliemann J; Christensen EI; Blasi F
    J Cell Biol; 1995 Dec; 131(6 Pt 1):1609-22. PubMed ID: 8522616
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Ab initio molecular orbital calculations on specific interactions between urokinase-type plasminogen activator and its receptor.
    Nagase K; Kobayashi H; Yoshikawa E; Kurita N
    J Mol Graph Model; 2009 Aug; 28(1):46-53. PubMed ID: 19403319
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The urokinase receptor (uPAR, CD87) as a target for tumor therapy: uPA-silica particles (SP-uPA) as a new tool for assessing synthetic peptides to interfere with uPA/uPA-receptor interaction.
    Guthaus E; Schmiedeberg N; Bürgle M; Magdolen V; Kessler H; Schmitt M
    Recent Results Cancer Res; 2003; 162():3-14. PubMed ID: 12790317
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Urokinase-mediated posttranscriptional regulation of urokinase-receptor expression in non small cell lung carcinoma.
    Montuori N; Mattiello A; Mancini A; Taglialatela P; Caputi M; Rossi G; Ragno P
    Int J Cancer; 2003 Jun; 105(3):353-60. PubMed ID: 12704669
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.